Econazole or its saltsPDL |
|
I |
DEC / 13 |
Ecothiophate or its saltsPDL |
|
I |
DEC / 13 |
Ectylurea or its saltsPDL |
|
I |
DEC / 13 |
EculizumabPDL |
|
I |
DEC / 13 |
Edaravone or its derivatives PDL |
|
I |
NOV / 19 |
Edoxaban or its saltsPDL |
|
I |
FEB / 17 |
Edrophonium chloridePDL |
|
I |
DEC / 13 |
EfalizumabPDL |
|
I |
DEC / 13 |
EfavirenzPDL |
|
I |
DEC / 13 |
EfinaconazolePDL |
|
I |
DEC / 13 |
Eflornithine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Elagolix or its salts PDL |
|
I |
DEC / 18 |
Elbasvir or its saltsPDL |
|
I |
AUG / 16 |
Eletriptan or its saltsPDL |
|
I |
DEC / 13 |
Elexacaftor or its saltsPDL |
|
I |
SEP / 21 |
Eliglustat or its saltsPDL |
|
I |
MAY / 17 |
Elosulfase alfaPDL |
|
I |
AUG / 14 |
ElotuzumabPDL |
|
I |
AUG / 16 |
Eltrombopag or its saltsPDL |
including but not limited to eltrombopag olamine
|
I |
DEC / 13 |
Eluxadoline or its saltsPDL |
|
I |
APR / 17 |
Elvitegravir or its salts or derivativesPDL |
|
I |
DEC / 18 |
Emamectin or its saltsPDL |
including but not limited to emamectin benzoate
|
I |
DEC / 13 |
EmbutramidePDL |
|
I |
DEC / 13 |
Emedastine or its saltsPDL |
|
I |
DEC / 13 |
EmicizumabPDL |
|
I |
OCT / 18 |
EmpagliflozinPDL |
|
I |
OCT / 15 |
EmtricitabinePDL |
|
I |
DEC / 13 |
EmylcamatePDL |
|
I |
DEC / 13 |
Enalapril or its salts or derivativesPDL |
including but not limited to enalapril maleate
|
I |
DEC / 13 |
Enasidenib or its saltsPDL |
|
I |
MAR / 19 |
Encephalitis vaccine (Japanese) |
|
I |
FEB / 02 |
Encorafenib or its saltsPDL |
|
I |
MAY / 21 |
EnfluranePDL |
|
I |
DEC / 13 |
Enfortumab vedotinPDL |
|
I |
NOV / 21 |
EnfuvirtidePDL |
|
I |
DEC / 13 |
Enoxaparin or its saltsPDL |
|
I |
DEC / 13 |
EnrofloxacinPDL |
|
I |
DEC / 13 |
EntacaponePDL |
|
I |
DEC / 13 |
EntecavirPDL |
|
I |
DEC / 13 |
Entrectinib or its saltsPDL |
|
I |
JUL / 20 |
EnzalutamidePDL |
|
I |
DEC / 13 |
Ephedrine and its salts |
in preparations containing more than 8 mg per unit dose, or with a label recommending more than 8 mg/dose or 32 mg/day, or labelled or implied for use exceeding 7 days, or if indicated for other than nasal congestion.
|
I |
FEB / 02 |
Ephedrine and its salts in combination products |
in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. |
III |
APR / 06 |
Ephedrine and its salts in single entity products. |
in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. |
II |
APR / 06 |
Epinephrine and its salts |
in injectable form, EXCEPT in pre-filled syringes intended for emergency administration in the event of anaphylactic reactions to allergens
|
I |
SEP / 99 |
Epinephrine and its salts |
in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens |
II |
SEP / 99 |
Epinephrine or its saltsPDL |
Epinephrine topical solution for hemostasis when sold at a concentration equal to or greater than 1 mg/mL (1:1000)
|
I |
DEC / 21 |
Epirubicine or its saltsPDL |
|
I |
DEC / 13 |
EplerenonePDL |
|
I |
DEC / 13 |
Eprosartan or its salts or derivativesPDL |
|
I |
DEC / 13 |
EpsiprantelPDL |
|
I |
DEC / 13 |
Eptifibatide or its saltsPDL |
|
I |
DEC / 13 |
EptinezumabPDL |
|
I |
MAY / 21 |
Erdafitinib or its salts PDL |
|
I |
NOV / 19 |
ErenumabPDL |
|
I |
OCT / 18 |
Ergot alkaloids or their saltsPDL |
for human use
|
I |
DEC / 13 |
Eribulin or its salts or derivativesPDL |
including but not limited to eribulin mesylate
|
I |
DEC / 13 |
Erlotinib or its saltsPDL |
|
I |
DEC / 13 |
Ertugliflozin or its derivativesPDL |
|
I |
JUL / 18 |
Erythrityl tetranitrate |
|
I |
SEP / 98 |
Erythromycin or its salts or derivativesPDL |
Including but not limited to: azithromycin, clarithromycin, gamithromycin, telithromycin, tulathromycin
|
I |
DEC / 18 |
Erythropoiesis stimulating hormonePDL |
including but not limited to erythropoietin, darbepoetin alpha, epoetin alfa
|
I |
DEC / 13 |
Escitalopram or its saltsPDL |
|
I |
DEC / 13 |
Eslicarbazepine acetatePDL |
|
I |
AUG / 14 |
Esmolol or its saltsPDL |
|
I |
DEC / 13 |
Esomeprazole or its saltsPDL |
for veterinary use
|
I |
DEC / 13 |
Esomeprazole or its salts |
For human use, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole
|
III |
NOV / 18 |
Esomeprazole or its salts |
For human use, including but not limited to esomeprazole magnesium, EXCEPT when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole
|
I |
NOV / 18 |
Estramustine or its saltsPDL |
|
I |
DEC / 13 |
EtanerceptPDL |
|
I |
DEC / 13 |
Ethacrynic acidPDL |
|
I |
DEC / 13 |
Ethambutol or its saltsPDL |
|
I |
DEC / 13 |
Ethanolamine oleate |
|
II |
SEP / 98 |
EthchlorvynolTS |
|
I |
SEP / 98 |
EthinamateTS |
|
I |
SEP / 98 |
Ethionamide or its saltsPDL |
|
I |
DEC / 13 |
Ethoheptazine and its salts |
|
II |
SEP / 98 |
Ethomoxane or its saltsPDL |
|
I |
DEC / 13 |
Ethotoin or its saltsPDL |
|
I |
DEC / 13 |
Ethyl Chloride |
except in trace amounts |
II |
SEP / 98 |
Ethyl trichloramatePDL |
|
I |
DEC / 13 |
Ethylpapaverine and its salts |
|
I |
SEP / 98 |
Etidronic acid or its saltsPDL |
|
I |
DEC / 13 |
Etodolac or its salts or derivativesPDL |
|
I |
DEC / 13 |
Etomidate or its salts PDL |
|
I |
SEP / 20 |
Etoposide or its derivativesPDL |
|
I |
DEC / 13 |
Etravirine or its saltsPDL |
|
I |
DEC / 13 |
EtretinatePDL |
|
I |
DEC / 13 |
Etryptamine and its salts |
|
I |
SEP / 98 |
Etymemazine or its saltsPDL |
|
I |
DEC / 13 |
EvolocumabPDL |
|
I |
JAN / 16 |
ExemestanePDL |
|
I |
DEC / 13 |
Exenatide or its saltsPDL |
|
I |
DEC / 13 |
EzetimibePDL |
|
I |
DEC / 13 |
Ezogabine or its salts or derivativesPDL |
|
I |
DEC / 13 |